Nuvalent (NUVL)
(Delayed Data from NSDQ)
$74.11 USD
+1.95 (2.70%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $74.12 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Nuvalent, Inc. has a market cap of $5.18B, which represents its share price of $72.16 multiplied by its outstanding shares number of 71.81M. As a mid-cap company, NUVL's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NUVL 74.11 +1.95(2.70%)
Will NUVL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NUVL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVL
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
NUVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Sep 17, 2024
Other News for NUVL
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
Nuvalent Inc Reports Q2 2025 EPS of -$1.39, Missing Estimates; Net Loss Reaches $99.7 Million
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, ...
Paradigm Biocapital Advisors LP Acquires 1,128,613 Shares in Cidara Therapeutics Inc